Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Camrelizumab ± Famitinib in Recurrent/Metastatic Cervical Cancer
NCT04680988Phase 2Completed
- Sponsor
- Hengrui
- Start
- Apr 2021
- Primary completion
- Jul 2025
- Modality
- Small Molecules, Immune Checkpoint Inhibitors
- Countries
- 1
01
Overview
A Phase 2 trial of camrelizumab, famitinib in Cervical Cancer (CC), sponsored by Hengrui. Started Apr 2021; status: completed.
02
Drugs
camrelizumabfamitinib
03
Conditions
Cervical Cancer (CC)
Beyond the preview
Go deeper on NCT04680988.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04680988.